Korean J Schizophr Res.  2017 Apr;20(1):5-14. 10.16946/kjsr.2017.20.1.5.

The Effects on Metabolic Syndrome Parameters of Atypical Antipsychotic Agents in Schizophrenics Patients : 3 Years Retrospective Follow Up

• Bae HH
• Yoon HJ
• Park EK
• Lee JI

• KMID: 2387927
• DOI: http://doi.org/10.16946/kjsr.2017.20.1.5

Abstract

OBJECTIVES
Pharmacological treatment is critical on relapse prevention in patients with schizophrenia. However, atypical antipsychotic agents are known to cause weight gain more than typical agents despite their various effects. In addition, they are known to affect blood sugar, blood pressure, cholesterol, cardiac function, and sexual function. This study was designed to examine the effects on metabolic parameters when schizophrenic patients have been taken atypical antipsychotic agents.
METHODS
This was a trial in 137 patients with DSM-IV-TR schizophrenia who were admitted or treated in mental hospital. Anthropometric measurement and blood testing were conducted at baseline, 12 month, 36 month, and sociodemographic and treatment history were collected from medical records. We conducted height, weight, waist circumference, blood pressure, FBS, total cholesterol, HDL, triglyceride, and QTc interval. Metabolic syndrome was diagnosed by ATPIIIa criteria.
RESULTS
Aripiprazole showed the significant difference in the impact on weight, blood pressure, waist circumference, total cholesterol, HDL, triglyceride than paliperidone and olanzapine at 1-year and 3-year period. Olanzapine showed the significant increase of weight and triglyceride than paliperidone at 3-year period. The prevalence of metabolic syndrome increased in paliperidone at 1-year and in olanzapine at 3-year period compared to aripiprazole significantly.
CONCLUSION
We concluded that aripiprazole has less impact on the abdominal obesity, FBS, blood pressure, and cholesterol than paliperidone and olanzapine. Olanzapine showed the increase of long-term metabolic risk than other agents. There was needed the routine screening and multidisciplinary management of medical problems in schizophrenic patients for the prevention of metabolic syndrome.

Keyword

Schizophrenia; Atypical antipsychotics; Metabolic syndrome

MeSH Terms

Antipsychotic Agents*
Aripiprazole
Blood Glucose
Blood Pressure
Cholesterol
Cholesterol, HDL
Follow-Up Studies*
Hematologic Tests
Hospitals, Psychiatric
Humans
Mass Screening
Medical Records
Obesity, Abdominal
Paliperidone Palmitate
Prevalence
Retrospective Studies*
Schizophrenia
Secondary Prevention
Triglycerides
Waist Circumference
Weight Gain
Antipsychotic Agents
Aripiprazole
Blood Glucose
Cholesterol
Cholesterol, HDL
Paliperidone Palmitate

Reference

1). Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015; 9:297–303.

2). Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med. 2008; 38:103–112.

3). Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011; 26:291–302.

4). Papanastasiou E. The prevalence and machanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013; 3:33–51.

5). Stahl SM. Essential Psychopharmacology. 4th edition.New York, NY: Cambridge University Press;2013.

6). De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009a; 4:412–424.

7). Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008; 105:175–187.

8). Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012; 32:449–57.

9). Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012; 27:521–526.

0). Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incidence cardiovascular events and death: a systematic review and metaanalysis of longi-tudinal studies. J Am Coll Cardiol. 2007; 49:403–414.

11). Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk: a systematic review and metaanalysis. J Am Coll Cardiol. 2010; 56:1113–1132.

12). Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015; 14:339–347.

13). Hasnain M, Vieweg WV. QTc Interval prolongation and torsade de pointes associated with second-generation antipsychotics and anti-depressants: a comprehensive review. CNS Drugs. 2014; 28:887–920.

14). Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and metaanalysis. Schizophr Bull. 2013; 39:306–318.

15). Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and metaanalysis. Schizophr Bull. 2013; 39:306–318.

16). Ifteni P, Correll CU, Burtea V, Kane JM, Manu P. Sudden unex-pected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res. 2014; 155:72–76.

17). Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, et al. Attitudes toward metabolic adverse events among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat. 2016; 12:427–436.

18). American Psychiatric Association. The diagnostic and statistical manual of mental disorder. 4th ed, Washington DC, American Psychiatric Press. 1994.

19). McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003; 139:802–809.

20). Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752.

21). Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. A Joint In-terim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645.

22). Koponen H1. Alaräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry. 2008; 62:342–345.

23). Meyer JM, Koro CE. The effects of antipsychotic therapy on se-rum lipids: a comprehensive review. Schizophr Res. 2004; 70:1–17.

24). McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveg-gel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004; 65:47–56.

25). Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005; 118:15–22.

26). Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65:510–517.

27). Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62:22–31.

28). Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale. 2009; 35:330–339.

29). McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sulli-van L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005; 80:19–32.

30). Ko YK, Soh MA, Kang SH, Lee JI. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci. 2013; 11:80–88.

31). Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991; 36:239–245.

32). Kim DH, Choi SY, Choi EK, Suh JW, Lee W, Kim YS. Distribution of coronary artery calcification in an asymptomatic Korean population: association with risk factors of cardiovascular disease and metabolic syndrome. Korean Circ J. 2008; 38:29–35.

33). Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J. Increasing prevalence of metabolic syndrome in Korea; The Korean national health and nutrition examination survey for 1998-2007. Diabetes Care. 2011; 34:1323–1328. .34) Goldstein BJ. Insulin resistance: from benigh to type 2 diabetes mel-litus. Rev Cardiovasc Med 2003;4: S3-S10.35) Haupt DW. Different metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16: 149-155.